Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EKSO vs INTG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INTG Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

INTG Overall Winner 6-Pillar Tally: EKSO 1 – 4 INTG (1 Tie) Matrix Metrics: EKSO 2 – 6 INTG

As of Nov 20, 2026, Intergroup Corporation (The) (INTG) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas INTG carries 35.0/100 (SELL) at $35.58 (N/M Forward P/E, 14.4% operating margin).

  • Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. INTG 35.0/100 SELL), INTG captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (14.4% vs. -119.7% operating margin) and revenue trajectory (-6.9% vs. -38.3% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs INTG
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
INTG NASDAQ Head-to-Head Winner
Intergroup Corporation (The)
Operators Of Apartment Buildings
$35.58
-2.23% 1D
Market Cap $78.2M
TTM Revenue $73M
Forward P/E N/M
Beta / 30D Vol -0.06β · 52% Vol
Unified Composite Score
35.0 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.7 · SMA20: $38.60 · SMA50: $35.36

6-Pillar Scorecard Institutional Category Breakdown (EKSO 1 – 4 INTG)

Columns: Metric · EKSO · INTG
1. Valuation Multiples EKSO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x 3.6x
2. Growth & Scale INTG
Revenue Growth (YoY) -38.3% -6.9%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $13M $73M
Market Cap $42.0M $78.2M
3. Profitability & Quality INTG
Gross Margin 53.5% 27.9%
Operating Margin -119.7% 14.4%
Net Profit Margin -91.4% 0.8%
Return on Equity (ROE) -107.6% 0.0%
4. Balance Sheet & Cash Flow INTG
Cash Generation (TTM) -$11M EBITDA $2.8M
Cash Flow Margin -86.0% EBITDA Mgn 3.9%
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $186M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat INTG
OpEx & R&D Intensity N/A 13.5% of Rev ($9.8M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Lodging Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (2) vs INTG (6)
Institutional Metric EKSO INTG Criterion Row Edge
Market Capitalization
Scale
$42.0M $78.2M Larger Scale INTG
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.3% -6.9% Higher Growth INTG
Operating Margin (TTM)
Profitability
-119.7% 14.4% Higher Margin INTG
Net Profit Margin
Profitability
-91.4% 0.8% Higher Margin INTG
Return on Equity (ROE)
Capital Efficiency
-107.6% 0.0% Higher ROE INTG
52-Week Range Position
Momentum
87% ($0–$14) 39% ($25–$52) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol -0.06β · 52% Vol Lower Realized Risk INTG
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 35.0 / 100 (SELL) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$13M $73M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% 27.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) $2.8M ($186M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +22.22 pp
EKSO: +25.53% · INTG: +3.31%
3M Horizon INTG +6.67 pp
EKSO: +25.93% · INTG: +32.6%
6M Horizon EKSO +164.56 pp
EKSO: +182.63% · INTG: +18.07%
1Y Horizon EKSO +164.56 pp
EKSO: +182.63% · INTG: +18.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs INTG. Trailing 12-month operating profitability (EKSO -119.7% vs INTG 14.4%) and valuation multiples (EKSO N/M vs INTG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
INTG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$73M
Gross Margin27.9%
Op. Margin14.4%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INTG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact INTG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INTG Moat Profile Cyclical / Execution-Driven Positioning
Lodging Operator
Competes within the Lodging value chain with $78.2M market capitalization and 14.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($9.8M)
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs INTG Key Questions & Quantitative Answers

As of Nov 20, 2026, Intergroup Corporation (The) (INTG) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas INTG carries 35.0/100 (SELL) at $35.58 (N/M Forward P/E, 14.4% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. INTG 35.0/100 SELL), INTG captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (14.4% vs. -119.7% operating margin) and revenue trajectory (-6.9% vs. -38.3% YoY).

INTG leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with INTG at -6.9% YoY revenue growth and N/A YoY earnings growth on $73M TTM revenue (27.9% gross margin, 14.4% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $73M for INTG. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($9.8M) (0 disclosures) for INTG.

EKSO screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas INTG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.6x EV/Revenue (3.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus INTG (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, INTG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.06β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.